Sarepta Duchenne gene therapy wins broader use from FDA
The Food and Drug Administration has substantially loosened limits on the first gene therapy for Duchenne muscular dystrophy in a
July 1, 2024
The Food and Drug Administration has substantially loosened limits on the first gene therapy for Duchenne muscular dystrophy in a
Today, a brief rundown of news from Belharra Therapeutics, AstraZeneca, Regenxbio and Tasyha Gene Therapies. Sanofi will work with biotechnology
Dive Brief: Intra-Cellular Therapies plans to seek clearance to sell its medicine Caplyta for patients with depression after a second-late
Dive Brief: The Food and Drug Administration on Monday approved a new vaccine from Merck & Co. that protects against
The failure of a Pfizer medicine for Duchenne muscular dystrophy adds new uncertainty around the effectiveness of gene therapy for
Today, a brief rundown of news from Takeda and the Food and Drug Administration, as well as updates from Insmed,
Dive Brief: Telix, an Australia-based developer of radiopharmaceutical drugs for cancer, has canceled plans to raise roughly $200 million via
AbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate
Dive Brief: Moderna said its next-generation COVID-19 vaccine succeeded in a Phase 3 study, offering increased effectiveness for adults. The
The Supreme Court on Thursday unanimously ruled an anti-abortion group contesting the Food and Drug Administration’s approval of the abortion